Why Aurinia’s new Lupkynis trial could change the lupus nephritis treatment sequence
Discover how Aurinia’s PRESERVE study could reshape lupus nephritis care by combining Lupkynis with three major biologic therapies.
Pharma & Biotech
Pharma & Biotech
Qihan Biotech gains FDA momentum for QT-019B as allogeneic CAR-T ambitions grow
Find out how Qihan Biotech’s QT-019B FDA designations could reshape autoimmune CAR-T development and what risks remain.
Pharma & Biotech
Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout
See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!
Pharma & Biotech
How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.
Pharma & Biotech
FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.
Pharma & Biotech
Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Medical Devices & Diagnostics
Why 10x Genomics is betting on peripheral blood to decode complex immune disorders
Find out how 10x Genomics and Brigham & Women's Hospital are using single-cell profiling to redefine autoimmune diagnostics. Can it change patient care?
Pharma & Biotech
AstraZeneca gains EU approval for Saphnelo self-injection pen in lupus treatment
AstraZeneca has received European Commission approval for a new subcutaneous formulation of Saphnelo (anifrolumab), allowing adult patients with systemic lupus erythematosus (SLE) to self-administer the drug via a once-weekly pre-filled pen. The regulatory decision follows a positive opinion from the Committee for Medicinal Products for Human Use and is supported by data from the Phase